Revolution Medicines Q4 Sales $700.00K Miss $1.09M Estimate
Portfolio Pulse from Benzinga Newsdesk
Revolution Medicines (NASDAQ:RVMD) reported Q4 sales of $700K, missing the consensus estimate of $1.09M by 35.83%. This represents a 95.43% decrease from the same period last year, where sales were $15.33M.
February 26, 2024 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revolution Medicines reported significantly lower Q4 sales than expected, missing estimates by 35.83% and experiencing a 95.43% decrease from the previous year.
The significant miss in quarterly sales compared to analyst expectations and the drastic decrease from the previous year's sales are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100